Cardiology Today Current Issue

The following articles appeared in the print edition of Cardiology Today.

Table of Contents

• Antithrombotic therapy after PCI in AF requires careful consideration
• Progress documented, knowledge gaps identified at cardio-oncology workshop Nonniekaye Shelbourne, MS, CRNP, AOCN; Patrice Desvigne-Nickens, MD; Bishow Adhikari, PhD; Lori Minasian, MD, FACP
• FDA agrees to consider CV outcomes indication for alirocumab
• FDA approves patisiran infusion for hereditary transthyretin-mediated amyloidosis
• In memoriam: Joseph D. Babb, MD, MSCAI
• In memoriam: Ronald G. Victor, MD
• AHA updates definition of resistant hypertension, addresses management in new scientific statement
• Expert panel endorses genetic screening for FH
• HDL not as cardioprotective in postmenopausal women
• Panel favors PFO closure plus antiplatelet therapy for stroke prevention
• Statins may not affect outcomes in older patients without diabetes, CVD
• USPSTF: Evidence insufficient on benefits, risks of ECG to diagnose AF
• ARRIVE: Aspirin does not reduce initial vascular events in low-to-moderate risk population
• ASCEND: Aspirin, omega-3 supplements fail for primary prevention in diabetes
• COMMANDER HF: Low-dose rivaroxaban not effective in HF with sinus rhythm and CAD
• GLOBAL LEADERS: Long-term ticagrelor monotherapy not superior to standard DAPT
• MITRA-FR: MitraClip does not change prognosis in HFrEF, mitral regurgitation
• No excess CV risk with lorcaserin for weight loss
• PURE: Moderate red meat, dairy intake may help reduce mortality, CV risk
• Results mixed on rivaroxaban for extended thromboprophylaxis in MARINER
• VIDEO: New treatment option for rare cardiomyopathy may 'change lives'
• Do not go with the flow: Stemming the tide of GI bleeding with continuous-flow VADs Alana M. Ciolek, PharmD, BCPS; Audrey J. Littlefield, PharmD, BCPS, BCCP; Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ Cardiology)
• Trial Scorecard: ARRIVE
• Trial Scorecard: ASCEND
• Trial Scorecard: BASKET-SMALL 2
• Trial Scorecard: COMMANDER-HF
• Trial Scorecard: FREED
• Trial Scorecard: GLOBAL LEADERS
• Trial Scorecard: MARINER
• Trial Scorecard: POET